Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBLe: Nivolumab +/- Ipilimumab in POLE/POLD1 Mutated Solid Tumors
NCT03461952Phase 2Terminated
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in solid tumor (advanced stage), sponsored by Canadian Cancer Trials Group. Started Mar 2019; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03461952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461952.